Rekah Pharmaceutical Prod (XTAE:REKA) Beta: 0.3186 (As of Jun. 27, 2026)


XTAE:REKA Rekah Pharmaceutical Prod Ltd XTAE:REKA
57 GF Score
Price ₪10.62
GF Value ₪13.05
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Rekah Pharmaceutical Prod Beta?

Rekah Pharmaceutical Prod XTAE:REKA 57 Beta is 0.3186 as of Jun. 27, 2026. GuruFocus rates XTAE:REKA with a GF Score™ of 57/100 and a GF Value™ of ₪13.05 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-27), Rekah Pharmaceutical Prod's Beta is 0.3186.


Rekah Pharmaceutical Prod  (XTAE:REKA) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Rekah Pharmaceutical Prod Beta Related Terms


Rekah Pharmaceutical Prod Beta Historical Data

* Premium members only.

The historical data trend for Rekah Pharmaceutical Prod's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rekah Pharmaceutical Prod Beta Chart

Rekah Pharmaceutical Prod Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.04 0.19 0.29 0.11 0.09

Rekah Pharmaceutical Prod Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.22 0.21 0.16 0.09 0.29

XTAE:REKA vs ZTS, UTHR, VTRS: Beta Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Rekah Pharmaceutical Prod's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rekah Pharmaceutical Prod Beta vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Rekah Pharmaceutical Prod's Beta distribution charts can be found below:

* The bar in red indicates where Rekah Pharmaceutical Prod's Beta falls into.


XTAE:REKA
57GF Score
Rekah Pharmaceutical Prod Ltd XTAE:REKA
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rekah Pharmaceutical Prod Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 0.3186 mean?
Rekah Pharmaceutical Prod (XTAE:REKA) has a Beta of 0.3186 as of Jun. 27, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Rekah Pharmaceutical Prod and its competitors.
Is Rekah Pharmaceutical Prod's Beta too high?
Rekah Pharmaceutical Prod's current Beta is 0.3186. Overall, Rekah Pharmaceutical Prod has a GF Score™ of 57/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Rekah Pharmaceutical Prod's Beta compare to ZTS and UTHR?
Rekah Pharmaceutical Prod's Beta of 0.3186 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Drug Manufacturers company?
A good Beta depends on the Drug Manufacturers industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Rekah Pharmaceutical Prod and its competitors. Rekah Pharmaceutical Prod's current Beta is 0.3186. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rekah Pharmaceutical Prod stock overvalued right now?
Based on GuruFocus' analysis, Rekah Pharmaceutical Prod (XTAE:REKA) is currently considered Modestly Undervalued. The stock's GF Value™ is ₪13.05, compared to a current price of ₪10.62 — trading 18.6% below its estimated fair value. The current Beta is 0.3186. Rekah Pharmaceutical Prod's overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Rekah Pharmaceutical Prod (XTAE:REKA), the current Beta is 0.3186 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Rekah Pharmaceutical Prod (XTAE:REKA) Overvalued in 2026?

Based on GuruFocus' analysis, Rekah Pharmaceutical Prod stock appears to be undervalued. The current stock price of ₪10.62 is trading 18.6% below its estimated GF Value™ of ₪13.05. GuruFocus considers Rekah Pharmaceutical Prod to be Modestly Undervalued.

Key valuation signals for XTAE:REKA:

  • Beta: 0.3186
  • GF Value™: ₪13.05 vs. price of ₪10.62 (18.6% below fair value)
  • GF Score™: 57/100 with 3 warning signs

No single metric tells the full story. See the XTAE:REKA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Rekah Pharmaceutical Prod Business Description

Address 30 Hamelacha Street, Holon, ISR
Rekah Pharmaceutical Prod Ltd is engaged in the manufacturing, importing, marketing, and distribution of pharmaceuticals and cosmetics. It primarily caters to the needs of hospitals, retirement homes, and national medical healthcare services.
57GF Score

Get the complete analysis for XTAE:REKA

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₪10.62
Price
₪13.05
GF Value